The global irritable bowel syndrome treatment market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing prevalence of target disease and rising uptake of drugs. In different regions commercialization of existing products is growing which drives the market. Rising acceptance of Linzess in the U.S., Japan, and Europe is contributing in the revenue growth.
Irritable bowel syndrome (IBS) is most common gastrointestinal disorder affecting large intestine, with prevalence rate of around 10-12%, globally. Symptoms and signs include bloating, cramping, gas, constipation, abdominal pain, and diarrhea. Irritable bowel syndrome treatment includes change in diet, counselling, stress relief, and proper medicines. The particular cause of symptoms is indefinite but it may disturb interaction between brain, nervous system, and gut. Due to this, changes occur in bowel sensation and movement. Based on survey conducted by the International Foundation for Gastrointestinal Disorders (IFFGD), around 2,050 IBS patients said that diagnosis of their conditions was completed 6.6 years after their symptoms initiated.
The market is neglected, with large number of opportunities for pharmaceutical companies to talk about numerous unmet needs in the therapy. Under clinical trials there are some promising products which increases the speed of the growth. Product sales are anticipated to raise considerably during the forecast period, majorly owing to growing prevalent population and commercialization of novel drugs for the treatment of constipation-predominant IBS.
Around 25-45% of patients take appointment of gastroenterologists because of symptoms of IBS. Still huge number of people are undiagnosed and unconscious about their symptoms which shows a medically known disorder. Because of this, various awareness campaigns are need to be organized to increase awareness about the condition. For instance, in April 2018, in the U.K., The IBS network conducted various activities to overcome the stigma about illness.
The report on the global irritable bowel syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes | Details |
Report Title | Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year | 2020 |
Historic Data | 2018–2019 |
Forecast Period | 2021–2028 |
Segmentation | Types (Constipation-predominant [Linzess/Constella, Amitiza, and Others], Diarrhea-predominant [Xifaxan, Viberzi, and Others]), Products (Xifaxan, Linzess/Constella, Viberzi, Amitiza, and Others) |
Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report | Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx |
IBS-C segment is expected to grow at a rapid pace
Based on types, the irritable bowel syndrome treatment market is divided into constipation-predominant (IBS-C) and diarrhea-predominant (IBS-D). The IBS-C segment is subdivided into linzess/constella, amitiza, and others. Also, the IBS-D segment is subdivided into xifaxan, viberzi, and others.
The IBS-C segment accounted for key share of the market due to growing prevalence of target diseases and increasing uptake of drugs including Linzess/Constella and Amitiza. Moreover, the segment is anticipated to expand at a rapid pace during the forecast period owing to projected launch of products such as Tenapanor and SYN-010. These products are presently under clinical trials. Astellas Pharma, AstraZeneca, Ironwood Pharmaceuticals, Inc., and Allergan are some key players present in this segment.
Linzess/Constella segment is projected to hold a key market share
On the basis of products, the irritable bowel syndrome treatment market is segmented into xifaxan, linzess/constella, viberzi, amitiza, and others. The linzess/constella (linaclotide) segment is expected to hold a key share of the market during the forecast period owing to growing adoption of products in major regions including Japan, the U.S., Germany, UK, Italy, and Spain. In the U.S., Ironwood and Allergan marketed Linaclotide as a Linzess and in Europe Linaclotide is marketed as Constella by Allergan.
North America is expected to dominate the market
On the basis of regions, the irritable bowel syndrome treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is expected to exhibit a rapid growth rate in the coming years owing to existence of major market players, larger awareness among patients, huge presence of novel products, and well-established healthcare infrastructure.
On the other hand, the market of Europe is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing commercialization of IBS products, growing initiatives to increase awareness about disorder among people, and presence of a large target population.
Key players competing in the irritable bowel syndrome treatment market are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in April 2015, Salix Pharmaceuticals was acquired by Bausch Health for expansion of its portfolio by focusing on gastrointestinal drugs. Also, in January 2019, AstraZeneca and Ironwood Pharmaceuticals got marketing approval of Linzess in China to make stronger position in the market.
Some other reports from this category!